Eli Lilly and Company (NYSE:LLY) Upgraded by Berenberg Bank to Strong-Buy Rating

Eli Lilly and Company (NYSE:LLY) was upgraded by Berenberg Bank from a “hold” rating to a “strong-buy” rating in a report issued on Tuesday, Zacks reports.

Other research analysts have also recently issued research reports about the company. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Morgan Stanley restated an “overweight” rating and issued a $1,419.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 6th. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Sanford C. Bernstein upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 14th. Finally, Bank of America increased their price objective on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,304.86.

Eli Lilly and Company Stock Down 0.1%

NYSE LLY opened at $1,136.82 on Tuesday. The business has a fifty day moving average price of $1,180.50 and a two-hundred day moving average price of $1,074.73. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a fifty-two week low of $712.05 and a fifty-two week high of $1,292.65. The stock has a market capitalization of $1.07 trillion, a PE ratio of 38.15, a PEG ratio of 1.40 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter last year, the company posted $6.31 EPS. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts expect that Eli Lilly and Company will post 36.53 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last 90 days. Corporate insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. boosted its position in shares of Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. Capital World Investors increased its position in Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after buying an additional 61,851 shares in the last quarter. Bank of America Corp DE acquired a new position in Eli Lilly and Company during the 2nd quarter worth approximately $13,522,666,000. Norges Bank acquired a new position in Eli Lilly and Company during the 4th quarter worth approximately $12,976,634,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after acquiring an additional 137,364 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Berenberg upgraded Eli Lilly to Buy and set a $1,400 price target, implying roughly 25% upside. Analyst Kerry Holford cited the company’s potential to extend its lead in the rapidly expanding obesity-drug market and deliver upside to 2026 guidance. Berenberg bullish on Eli Lilly, sees nearly 25% upside
• Positive Sentiment: Foundayo is gaining traction quickly in the U.S. oral weight-loss market. Lilly said the newly launched medicine has captured more than 30% of new patients starting oral weight-loss treatments, narrowing Novo’s early lead with its Wegovy pill. The market-share progress could strengthen expectations for Foundayo’s commercial contribution. Lilly says Foundayo has captured over 30% of new U.S. patients
• Positive Sentiment: Upcoming clinical data could support Lilly’s pipeline valuation. At the EASD 2026 meeting, Lilly plans to present data on Foundayo, investigational retatrutide and eloraTZP. Retatrutide’s reported weight-loss and A1C improvements, along with Foundayo diabetes data, reinforce the company’s prospects beyond Mounjaro and Zepbound. Lilly to present new cardiometabolic data at EASD 2026
• Positive Sentiment: Lilly is expanding its research platform through a QurCan collaboration. The agreement includes a strategic investment and access to QurCan’s genetic-medicine delivery technology, potentially broadening Lilly’s neuroscience and nucleic-acid therapy pipeline. QurCan and Lilly research collaboration
• Neutral Sentiment: The main investment risk is execution: Lilly’s premium valuation and future growth expectations depend heavily on continued clinical success, manufacturing expansion and sustained demand for obesity treatments.
• Negative Sentiment: Competition from Novo remains intense, while reports of unapproved or bootleg versions of Lilly’s experimental medicines highlight regulatory and reputational risks. These issues could complicate market access and commercialization.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.